Caliway Biopharmaceuticals Co., Ltd. (TPEX: 6919)
Taiwan
· Delayed Price · Currency is TWD 541.00
-14.00 (-2.52%)
Sep 10, 2024, 2:59 PM CST
Caliway Biopharmaceuticals Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Net Income | -622.43 | -488.46 | -286.16 | -224.29 | -98.49 | -121.83 |
| Depreciation & Amortization | 28.65 | 27.87 | 25.34 | 23.28 | 18.21 | 22.47 |
| Loss (Gain) From Sale of Assets | - | - | 0.11 | - | - | - |
| Stock-Based Compensation | 20.41 | 22.98 | 19.71 | 74.76 | 8.28 | 0.03 |
| Other Operating Activities | -1.4 | -0.35 | -0.36 | -3.27 | 0.86 | 2.43 |
| Change in Accounts Receivable | 1.65 | -4.77 | -3.12 | - | 3.2 | -3.2 |
| Change in Inventory | -2.35 | 1.78 | -2.76 | 2.48 | -2.51 | 0.43 |
| Change in Accounts Payable | -0.59 | -0.83 | 2.21 | -0.41 | -0.3 | 1.04 |
| Change in Unearned Revenue | 1.48 | -3.47 | 4.5 | - | - | - |
| Change in Other Net Operating Assets | 24.41 | 21.32 | -2.22 | 16.77 | 23.51 | -7.9 |
| Operating Cash Flow | -550.17 | -423.94 | -242.76 | -110.7 | -47.24 | -106.53 |
| Capital Expenditures | -14.03 | -8.6 | -14.16 | -14.9 | - | - |
| Sale of Property, Plant & Equipment | - | - | 0 | - | - | - |
| Sale (Purchase) of Intangibles | -1.67 | -1.09 | - | - | - | -0.31 |
| Investment in Securities | -309.69 | 166.78 | -456.18 | - | - | - |
| Other Investing Activities | 0.01 | 0.01 | -0.2 | - | - | 0.15 |
| Investing Cash Flow | -325.38 | 157.09 | -470.54 | -14.9 | -2.31 | -13.39 |
| Short-Term Debt Issued | - | - | - | - | - | 5 |
| Long-Term Debt Issued | - | - | - | - | 8.13 | 106.73 |
| Total Debt Issued | - | - | - | - | 8.13 | 111.73 |
| Short-Term Debt Repaid | - | - | - | - | -5 | - |
| Long-Term Debt Repaid | - | -8.22 | -12.6 | -93.98 | -27.83 | -7.86 |
| Total Debt Repaid | -8.35 | -8.22 | -12.6 | -93.98 | -32.83 | -7.86 |
| Net Debt Issued (Repaid) | -8.35 | -8.22 | -12.6 | -93.98 | -24.7 | 103.86 |
| Issuance of Common Stock | 3,043 | 3,042 | 784.32 | 720.88 | 147.43 | - |
| Repurchase of Common Stock | - | - | - | -0.09 | - | - |
| Financing Cash Flow | 3,034 | 3,034 | 771.72 | 626.81 | 122.74 | 103.86 |
| Foreign Exchange Rate Adjustments | 0.75 | 0.32 | 1.73 | 0.14 | -1.32 | 0.28 |
| Net Cash Flow | 2,160 | 2,767 | 60.15 | 501.35 | 71.87 | -15.79 |
| Free Cash Flow | -564.2 | -432.54 | -256.93 | -125.6 | -47.24 | -106.53 |
| Free Cash Flow Margin | -1588.62% | -1111.01% | -2004.12% | -1017.90% | -456.41% | -571.23% |
| Free Cash Flow Per Share | -4.27 | -3.49 | -2.19 | -1.37 | -0.63 | -1.52 |
| Cash Interest Paid | 0.42 | 0.5 | 0.67 | 6.18 | 3.65 | 1.26 |
| Cash Income Tax Paid | - | - | - | 0.03 | 0.09 | 0.03 |
| Levered Free Cash Flow | -365.49 | -266.4 | -171.06 | -74 | -17.57 | - |
| Unlevered Free Cash Flow | -365.23 | -266.09 | -170.65 | -72.19 | -14.75 | - |
| Change in Net Working Capital | -23.21 | -13.68 | 1.76 | 11.11 | -24.77 | - |
Source: S&P Capital IQ. Standard template. Financial Sources.